Details:
Ipsen to conduct further assessment of the complete data set and work with the regulatory authorities, based on encouraging therapeutic activity signals observed in preliminary post-hoc analyses.
Lead Product(s): Palovarotene
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2020